公开(公告)号：US11871775B2

公开(公告)日：2024-01-16

申请号：US16685445

申请日：2019-11-15

申请人： GLAC BIOTECH CO., LTD.

发明人： Pei-Shan Hsieh ,  Chung-Wei Kuo ,  Yi-Chun Tsai ,  Hsieh-Hsun Ho ,  Yi-Wei Kuo

IPC分类号： A23L33/135 ,  A61Q11/00 ,  A61K35/747 ,  A61P1/02 ,  A61K8/99 ,  A61K45/06 ,  A61Q17/00

CPC分类号： A23L33/135 ,  A61K8/99 ,  A61K35/747 ,  A61K45/06 ,  A61P1/02 ,  A61Q11/00 ,  A61Q17/005 ,  A23V2002/00 ,  A23V2002/00 ,  A23V2200/312 ,  A23V2400/113 ,  A23V2002/00 ,  A23V2200/312 ,  A23V2400/181 ,  A23V2002/00 ,  A23V2200/312 ,  A23V2400/173 ,  A23V2002/00 ,  A23V2200/312 ,  A23V2400/175 ,  A23V2002/00 ,  A23V2200/312 ,  A23V2400/165 ,  A23V2002/00 ,  A23V2200/312 ,  A23V2400/147

摘要： A method of inhibiting oral pathogens comprising administering to a subject in need thereof an effective amount of Lactobacillus strain-containing food composite, medical composite and oral cleaning composite. The food composite, medical composite and oral cleaning composite comprises at least one Lactobacillus strain, which is at least one isolated Lactobacillus strain selected from a group including Lactobacillus acidophilus F-1 strain, CCTCC NO: M2011124; Lactobacillus salivarius subsp. salicinius AP-32 strain, CCTCC NO: M2011127; Lactobacillus reuteri GL-104 strain, CCTCC NO: M209138; Lactobacillus paracasei GL-156 strain, CCTCC NO: M2014590; Lactobacillus helveticus RE-78 strain, CGMCC No. 13513; Lactobacillus rhamnosus CT-53 strain, CCTCC NO: M2011129; and Lactobacillus paracasei ET-66 strain, CGMCC No. 13514, which are respectively preserved in China Center for Type Culture Collection (CCTCC) and China General Microbiological Culture Collection Center (CGMCC).

公开(公告)号：US20200330530A1

公开(公告)日：2020-10-22

申请号：US16389297

申请日：2019-04-19

申请人： GLAC BIOTECH CO., LTD.

发明人： Pei-Shan Hsieh ,  HSIEH-HSUN HO ,  Yi-Chun Tsai ,  Chung-Wei Kuo

IPC分类号： A61K35/747 ,  A61K9/00

摘要： At least one isolated lactic acid bacteria strains selected from the following: TSP05 (Lactobacillus plantarum), TSF331 (Lactobacillus fermentum) and TSR332 (Lactobacillus reuteri) is provided. The above-mentioned active or inactive lactic acid bacteria strains have a function of hepatoprotection and is used in a form of a food composition or a pharmaceutical composition.

公开(公告)号：US11612171B2

公开(公告)日：2023-03-28

申请号：US16599496

申请日：2019-10-11

申请人： GLAC BIOTECH CO., LTD.

发明人： Pei-Shan Hsieh ,  Chung-Wei Kuo ,  Yi-Chun Tsai ,  Hsieh-Hsun Ho ,  Yi Wei Kuo

IPC分类号： A23C9/123 ,  A23C19/032 ,  A23C19/06 ,  A61P3/10 ,  A61K35/747

摘要： A food composition and pharmaceutical composition with strains of lactic acid bacteria for modulating blood glucose are provided, comprising an isolated lactic acid bacteria strain. The isolated lactic acid bacteria strain is at least one selected from a group including a GL-104 strain of Lactobacillus reuteri (CCTCC NO: M209138), an AP-32 strain of Lactobacillus salivarius subsp. salicinius (CCTCC NO: M2011127), a TYCA06 strain of Lactobacillus acidophilus (CGMCC No: 15210), and an MH-68 strain of Lactobacillus johnsonii (CCTCC NO: M2011128), or a combination thereof.

公开(公告)号：US10993973B2

公开(公告)日：2021-05-04

申请号：US16039800

申请日：2018-07-19

申请人： Glac Biotech Co., Ltd

发明人： Pei-Shan Hsieh ,  Yi-Chun Tsai ,  Chung-Wei Kuo ,  Hsieh-Hsun Ho ,  Hung-Chih Lin ,  Jiu-Yao Wang

IPC分类号： A61K35/745 ,  A61K35/747 ,  A61P13/12 ,  A61L29/00 ,  A23L29/00

摘要： The present invention provides a lactobacillus strain-containing pharmaceutical composition and food composition for improving of kidney disease and inhibiting inflammation, which comprises an isolated lactic acid bacteria strain. The isolated lactic acid bacteria strain is at least one selected from a group including BLI-02 strain, CGMCC No. 15212, Bifidobacterium longum subsp. infantis, TYCA06 strain, CGMCC No. 15210, Lactobacillus acidophilus, VDD088 strain, CGMCC No. 15211, Bifidobacterium bifidum, and combinations thereof.

公开(公告)号：US11785975B2

公开(公告)日：2023-10-17

申请号：US17349366

申请日：2021-06-16

申请人： GLAC BIOTECH CO., LTD.

发明人： Pei-Shan Hsieh ,  Hsieh-Hsun Ho ,  Yi-Chun Tsai ,  Chung-Wei Kuo

IPC分类号： A23L33/135 ,  A61K35/747 ,  A61K9/00 ,  A61P13/00

CPC分类号： A23L33/135 ,  A61K9/0053 ,  A61K35/747 ,  A61P13/00 ,  A23V2002/00 ,  A23V2200/30 ,  A23Y2220/35 ,  A23Y2220/71

摘要： A food composition and pharmaceutical composition with strains of lactic acid bacteria for reducing blood uric acid concentration are provided, comprising at least one or two isolated lactic acid bacteria strains selected from the following two: TSF331 (Lactobacillus fermentum) and TSR332 (Lactobacillus reuteri).